Glycoprotein-Payload Conjugates via Enzymatic Glycosylation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody-drug conjugate (ADC) technologies face challenges in controlling the drug-to-antibody ratio (DAR) and payload diversity, leading to heterogeneity and immunogenicity issues, particularly in cancer therapy where the efficacy of therapeutic proteins needs improvement.
Innovation Solution
A process involving glycoprotein-payload conjugates is developed, utilizing a tri-mannosyl core structure modified by enzymes like β-N-acetylglucosaminidase and mannosyl (α-1,3-)/ (α-1,6-)-glycoprotein β-1,2-N-acetylglucosaminyltransferases to precisely control the conjugation of payloads, enabling homogeneous ADC production with controlled DAR and increased payload diversity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If random conjugation to lysine residues or cysteine residues is used, then the conjugation process is simple and easy to perform, but the drug-to-antibody ratio (DAR) cannot be controlled and product heterogeneity increases
Solution Approach 1:
The patent introduces an enzymatic glycosylation system as an intermediary mechanism. Glycosyltransferases are used to transfer sugar moieties to specific N-glycosylation sites on the antibody, enabling precise control of DAR without requiring direct chemical modification of amino acid residues. This enzymatic mediation resolves the contradiction by providing both specificity (controlling DAR) and operational simplicity (using enzyme-catalyzed reactions).
Solution Approach 2:
The patent changes the conjugation parameters from random chemical modification to controlled enzymatic glycosylation. By adjusting enzyme type, substrate availability, and reaction conditions, precise DAR values (0, 1, 2, or 4) can be achieved. This parameter change enables manufacturing precision while maintaining ease of manufacture through standardized enzymatic protocols.
2Manufacturing precision
If site-specific conjugation technologies (SMART-Tag, Thio-Bridge) are used, then DAR control and product homogeneity are improved, but mutation of natural antibodies causes PK and immunogenicity problems
Solution Approach 1:
The patent employs the antibody's own natural N-glycosylation machinery and sites to perform the conjugation function. By using endogenous N-glycosylation sites and glycosyltransferases, the system achieves site-specific conjugation without introducing foreign mutations. This self-service approach maintains the antibody's natural structure and properties, avoiding immunogenicity and PK issues while achieving precise DAR control.
3Ease of manufacture
If conventional ADC technologies are used, then the conjugation process is straightforward, but payload diversity is limited and therapeutic efficacy needs improvement
Solution Approach 1:
The patent creates a universal glycosylation-based conjugation platform that can accommodate multiple different payloads. The same enzymatic glycosylation system can be used with various sugar moieties and linker-payload conjugates, enabling diverse payloads (cytotoxic drugs, radioisotopes, imaging agents) to be attached to the same antibody scaffold. This multi-functionality resolves the contradiction by providing both ease of manufacture and payload diversity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach results in homogeneous ADC products with precise control over payload conjugation, enhancing therapeutic efficacy and reducing immunogenicity, thereby improving cancer treatment outcomes.
Implementation Method 1
reacting a glycoprotein comprising a glycan having formula (2) with β-N-acetylglucosaminidase to produce a modified glycoprotein comprising a tri-mannosyl core of formula (3)
Implementation Method 2
reacting the modified glycoprotein comprising the tri-mannosyl core of formula (3) with UDP-GlcNAc-(CH2)0-8—R, wherein R is azido, a ketone group or an aldehyde, in the presence of mannosyl (α-1,3-)-glycoprotein β-1,2-N-acetylglucosaminyltransferase
Implementation Method 3
reacting the modified glycoprotein comprising the tri-mannosyl core of formula (3) with UDP-GlcNAc-(CH2)0-8—R, wherein R is azido, a ketone group or an aldehyde, in the presence of mannosyl (α-1,6-)-glycoprotein β-1,2-N-acetylglucosaminyltransferase
Data Source
AI summary
A process for modifying glycoproteins is provided. The invention also provides a process for producing glycoprotein-payload conjugates, as well as the conjugates produced thereby.